Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TPT1 pseudogene 11 (TPT1P11) is classified as a processed pseudogene of the TPT1 gene. Processed pseudogenes are copies of mRNAs that have been reverse-transcribed and integrated back into the genome; they do not encode functional proteins and are generally not transcribed or translated. There is no evidence that TPT1P11 has any biological function, disease association, or therapeutic relevance. Unlike the functional TPT1 gene and its antisense lncRNA (TPT1-AS1), which have documented roles in cancer biology and cell proliferation, TPT1P11 is simply a non-functional genomic element. Pseudogenes are explicitly not considered therapeutic targets, receptors, enzymes, or active participants in biological pathways. No aliases, interacting drugs, or functions are ascribed to TPT1P11 in authoritative genetic databases or literature at this time. TPT1P11 is a pseudogene and not a therapeutic target. It has no known biological roles, mechanisms, or disease associations. Its mention as a drug target or functional molecule is incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TPT1 pseudogene 11 (TPT1P11).